EVALUATION OF PROGNOSIS IN PATIENTS WITH NON ST ELEVATION ACUTE CORONARY SYNDROMES WITH DIABETES MELLITUS OR METABOLIC Syndrome IN CORRELATION WITH INFLAMMATORY AND OXIDATIVE STRESS

E. Bobescu,H. Rus,E. Belu,A. Covaciu

Abstract:Aims: Evaluation of prognosis in patients with non ST el evation acute coronary syndromes (NSTE– ACS) and diabetes mellitus (DM) or metabolic syndro me (MS) in correlation with inflammatory and oxidative stress. Methods: 172 patients (pts) with NSTE-ACS were included in a prospective study for a period of 3 years and divided in three groups in relation with DM or MS association. Results: In NSTE-ACS patients with DM or MS it was observed a significant increased incidence of: lower than 40% ejection fraction (p<0.05); readmiss ion for heart failure III-IV NYHA class and unstabl e angina (p<0.05); acute myocardial infarction and ca rdiac death (p<0.05) at 3 years of follow up in comparison with NSTE-ACS non MS non DM group. It wa s no significant differences between NSTE-ACS with diabetes mellitus and with metabolic syndrome groups at 3 years. In NSTE-ACS patients, presence o f diabetes mellitus or metabolic syndrome were associ ated with significant higher incidence of inflammat ory (p<0.05, p<0.01) and oxidative stress (p<0.05) at 6 months. Conclusions: In non ST elevation acute coronary syndromes patie nts, the presence of diabetes mellitus or metabolic syndrome was associated with significant higher incidence of low ejection fraction, readmiss ion for heart failure III-IV NYHA class and unstable angin a, acute myocardial infarction and cardiac death at 3 years of follow up and with significantly increased inflamm atory and oxidative stress at 6 months. Key-words: acute coronary syndrome, metabolic syndrome, diabetes mellitus, inflammatory and oxidative stress Background The burden of cardiovascular disease (CVD) in Europe is responsible for over 2 mil cardiovascular deaths in EU -42% of total deathsand represent the main cause of disease burden 23% of total illness and death. [21, 24]. In patien ts with diabetes mellitus, 75% of deaths are represented by cardiovascular death; cardiovascular risk is 3-5 folds higher in diabetic’s patients and 3 folds higher in patients with metabolic syndrome. Incidence of metabolic syndrome in patients with acute coronary syndrome is 29-46%, with increased incidence of heart failure, and a higher long-term mortality compared to those without metabolic syndrome. [1-5,12,19] The main causes of this burden of disease in diabetes mellitus and metabolic syndrome patients are high LDL cholesterol, low HDL cholesterol serum values, prothrombotic status high plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, endothelial dysfunction, high leucocytes adhesively to endothelium and mycroalbuminuria [25,35]. Aim Evaluation of prognosis in patients with non ST elevation acute coronary syndromes (NSTE-ACS) and diabetes mellitus (DM) or metabolic syndrome (MS) in correlation with inflammatory and oxidative stress. Methods 172 patients (pts) with NSTE-ACS were included in a prospective study for a period of 36 months and divided in three groups in relation with MS or DM association. Clinical, electrocardiographic, echocardiographic evaluations were performed initial and at 1, 6, 12, 24 and 36 months, biologic evaluations were performed initial at 1 and 6 months. C-reactive protein serum level (Immuneturbidimetry method) and fibrinogen plasma level (Turbidimetry method) were determinate as markers of inflammatory Studiu original J.M.B. nr.22015 49 syndrome. Anti ox-LDL antibody titers (ELISA technique INOVA kit manufacturer) and total antioxidant status (TAS) serum level (ABTS ® Method-RANDOX kits) were measured for oxidative stress evaluation. Left ventricular ejection fraction was measured by 2-D Echocardiography, volume/dimension Simpson’s method. [59, 11, 14, 16, 31-33] Groups of study: NSTE-ACS non MS non DM 37 patients with NSTE-ACS without metabolic syndrome and diabetes mellitus; ACS MS 76 patients with an NSTE-ACS and metabolic syndrome; ACS DM – 59 patients with NSTEACS and diabetes mellitus ( Figure 1).

Medicine